Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SEA-CD70 · 1 trial · 2 indications
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
To be summarized using descriptive statistics.
To be summarized using descriptive statistics.
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | SEA-CD70 dose escalation cohort in relapsed/refractory (HMA-failure) MDS |
| Part B | EXPERIMENTAL | SEA-CD70 expansion cohort in relapsed/refractory (HMA-failure) MDS |
| Part C | EXPERIMENTAL | SEA-CD70 expansion cohort in relapsed/refractory AML |
| Part D | EXPERIMENTAL | SEA-CD70 + azacitidine dose-finding/dose optimization cohorts in relapsed/refractory MDS or MDS/AML, and previously untreated higher-risk MDS or MDS/AML |
| Part E | EXPERIMENTAL | SEA-CD70 + azacitidine expansion cohort in previously untreated higher-risk MDS or MDS/AML |
| Part F | EXPERIMENTAL | SEA-CD70 + azacitidine expansion cohort in relapsed/refractory MDS or MDS/AML |
| Part G | EXPERIMENTAL | SEA-CD70 + azacitidine +venetoclax dose-finding/dose optimization in previously untreated and unfit for induction therapy AML |
| Name | Type | Description |
|---|---|---|
| SEA-CD70 | DRUG | Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle |
| azacitidine | DRUG | 75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle. |
| Venetoclax | DRUG | 400 mg /day PO, continuously; administered with ramping |
Part A Inclusion Criteria * Participants with cytologically/histologically confirmed MDS (2016 World Health Organization (WHO) classification) with * Measurable disease per WHO MDS with excess blasts criteria * MDS that is relapsed or refractory and must not have other therapeutic options * ...
Top 20 of 34 competitors
SEA-CD40 is an investigational oncology drug being studied for the treatment of melanoma and myelodysplastic syndrome. It is in Phase 2 clinical development and is being developed by Pfizer, Inc. (NYSE: PFE).
SEA-CD40 is a small molecule that targets CD40, a protein involved in immune system regulation. By modulating this target, it aims to enhance the body's immune response against cancer cells. The drug is being evaluated in combination with other drugs in certain cancers.
SEA-CD40 is being developed by Pfizer, Inc., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical trials for oncology indications.
SEA-CD40 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy in patients with certain types of cancer.
SEA-CD40 is being studied in two clinical trials. One is NCT04993677, a Phase 2 study of SEA-CD40 given with other drugs in cancers including melanoma and non-small-cell lung carcinoma. Another is NCT04227847, a Phase 1 study of SEA-CD70 in myeloid malignancies, which is also listed under the drug's alternative name.
Yes, SEA-CD40 is also known as SEA-CD70. The drug has been referred to by both names in clinical trial registrations. For example, the Phase 1 trial NCT04227847 is titled 'A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies' and is associated with this drug.